Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report

被引：12

作者：

Chalmers, Anna ^{[1
]}

Jensen, Leif ^{[1
]}

Akerley, Wallace ^{[1
]}

机构：

[1] Univ Utah, Huntsman Canc Inst, Dept Internal Med, Div Oncol, 2000 Cir Hope Dr, Salt Lake City, UT 84112 USA

来源：

LUNG CANCER | 2017年 / 114卷

关键词：

Non-small cell lung cancer; Leptomeningeal metastases; Osimertinib; Epidermal growth factor receptor; CARCINOMATOSIS; ERLOTINIB; AZD9291; NSCLC; TKIS;

D O I：

10.1016/j.lungcan.2017.10.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In patients with non-small cell lung cancer (NSCLC) progression with leptomeningeal (LM) metastases is a catastrophic event with limited treatment options. We report a patient who developed leptomeningeal disease while on front-line erlotinib. High-dose tyrosine kinase inhibitor was started but ineffective. She was transitioned to third-generation TKI osimertinib, despite lacking a T790M mutation, and responded with complete resolution of symptoms and malignant cytology in the cerebrospinal fluid (CSF). Recent phase one data and our case indicate osimertinib should be viewed as a best practice for treatment of LM disease in epidermal growth factor receptor (EGFR) mutated NSCLC regardless of T790M status.

引用

页码：68 / 69

页数：2